Alkermes seeks to support research designed and conducted by independent clinicians and scientists through our Investigator Sponsored Studies (ISS) program.
ISS concepts related to our areas of interest are reviewed according to the schedule below. Alkermes may occasionally announce a Request for Proposals (RFP) for research in clinical areas where gaps in data have been identified. Submission deadlines for any RFP topics will be announced on this site.
The ISS research Alkermes supports must be based in the United States and is typically conducted by experienced researchers who have an established history of successfully completing research with independent funding.
Alkermes can provide its marketed products to the ISS programs it supports. In addition, there may be financial support available, but please note that study budgets cannot exceed $300,000 (inclusive of overhead).
Deadlines for Concept Notes: Jan. 31, 2024; April 29, 2024; Aug. 31, 2024
Substance Use Disorders
- Improving treatment initiation and adherence in AUD/OUD
- Long-term treatment outcomes, including real world data in AUD/OUD
- Neurologic profile of early recovery in OUD, including but not limited to sleep, cognition, and craving
- Digital technologies for assessment of physiological parameters (e.g. wearables) and/or treatment access and outcomes (e.g. telehealth) in AUD/OUD
- Implementing medication for AUD in healthcare systems
Schizophrenia
- Reduction in social burden (e.g. family, treatment team) through use of LAIs
- Demonstration of LAI benefits in specific comorbidities of schizophrenia (e.g. persistent substance problems) or subpopulations (e.g. persons with schizophrenia over the age of 60)
- Short-term and long-term economic and clinical outcomes of LAI treatment in schizophrenia using real-world data
- Outcomes research in schizophrenia and LAI use supporting continuity of care utilizing telehealth or other innovative technology-based approaches